As a result of the increased prevalence of diabetes, obesity and metabolic syndrome, non-alcoholic fatty liver disease (NAFLD) is now the most common chronic liver disease in developed country (1). NAFLD is a spectrum of pathologies ranging from benign hepatic steatosis through to non-alcoholic steatohepatitis (NASH), which can ultimately lead to cirrhosis and liver cancer. There are currently no FDA approved drugs for the treatment of NAFLD/NASH and there is a clear requirement for better models to understand this disease.
CN Bio, Cambridge, UK
AstraZeneca, Cambridge, UK